%20(3).png)
1 in 2 people will get cancer in their lifetime, and 40% of cancer patients use cannabis for treatment of symptoms. But clinical guidance for cannabis is difficult to find. That’s why Imerman Angels is partnering with EO Care — the first clinically guided cannabis health and wellness solution for employers, payers, and associations — to provide cannabis care and advice to members. ImermanAngels.org visitors will be able to access educational content including whether cannabis is right for them, how to optimize use, and even how to reduce use.
‍
Support Specifically Developed for Cancer Patients
“Many cancer patients find that cannabis gives them relief from their symptoms,” said Stephanie Lieber, Executive Director of Imerman Angels. “But even though it’s now legal in most states, clinical guidance is difficult to find. Physicians may recommend cannabis, but can’t prescribe it and don’t have the knowledge to give advice on forms and dosage. Patients are left relying on friends, family and retail dispensary staff for advice — none of whom are trained cannabis clinicians. This new partnership with EO Care will ensure that the Imerman Angels community has access to clinically based support specifically developed for cancer patients.”
‍
The Importance of Clinically Guided Cannabis Care
Medical cannabis — legal in 39 states — now helps many cancer patients manage their pain, nausea, sleeplessness and anxiety during treatment. In fact, up to 40% of patients with cancer use cannabis at some point along their cancer journey for treatment-related side effects, either during treatment or during survivorship. And for many patients, medical cannabis is less risky than opioids and other controlled substances when it comes to side effects and addiction.
‍
Brooke Worster, M.D., Director, Division of Supportive Oncology at Jefferson Health and Chief Medical Officer at EO Care, has performed groundbreaking research into the benefits of cannabis for cancer patients. “Today, many cancer patients are using cannabis without any guidance,” said Dr. Worster. “No one is checking for drug interactions, and some people are making themselves ill. EO Care is filling that gap, providing real clinical guidance for those seeking to use cannabis for health reasons.”
‍
“Cannabis has been proven by Dr. Worster and many others to have a measurable impact on relieving cancer and cancer treatment symptoms,” said Sean Collins, Co-founder and CEO of EO Care. “Through this partnership with Imerman Angels, we hope to help many more cancer patients make safe choices about using cannabis.”
‍
About Imerman Angels
Imerman Angels provides free cancer support for cancer fighters, survivors, previvors, and caregivers. Created based on the belief that no one should have to face cancer alone without the necessary support, Imerman Angels offers comfort and understanding through a one-on-one connection with someone who has been there.
‍
More About EO Care
EO Care is the first clinically guided cannabis health and wellness solution for employers, payers, and associations. Our digital health service gives HR and benefits leaders the necessary tools to help employees determine if cannabis should be part of their healthcare journey or not by providing clinical education and personalized care guidance. Built on data from over 18,000 cannabis clinician and patient interactions, EO Care provides clinician guidance and proprietary data models to help employers tackle unguided cannabis use and give employees an effective option for relief in cancer treatment, pain management, opioid replacement, anxiety, and sleep management. We’re led by a team of experts in CX healthcare, biotech and data intelligence.
‍
Learn More About Cannabis and Cancer Support
Explore our educational content on ImermanAngels.org — or discover more about clinically guided cannabis care on our site. For specific questions about cannabis and cancer support, try our Personalized Education Platform chatbot or connect with a Realm of Caring expert by calling (888) 823-6143.
Recently, the Department of Health and Human Services recommended that cannabis be reclassified from a Schedule I Controlled Substance to a Schedule III Controlled Substance under the federal Controlled Substances Act. In a PM360 article Rescheduling Cannabis to a Schedule III Controlled Substance: A Regulator’s Perspective,
As more states legalize the use of cannabis, it can be challenging for employers to keep up and find reliable information. A recent Benefits Pro article, Employees are more likely to apply for jobs that offer cannabis benefits, shares findings from an EO Care ...
Ethan Zohn truly embodies the word “survivor.” In 2001, he won Survivor Africa, the third season of the popular reality TV show — and later became a two-time survivor of a rare blood cancer. At the age of 35 and in the prime of his life, this fit, former professional soccer player was diagnosed with CD20+ Hodgkin’s Lymphoma. Over several years, Ethan endured aggressive treatment including two stem cell transplants.
Get special offers, event invites and the latest on new care offerings and product releases.
